Laura Moran
Partner
Litigation
Laura
Moran
Laura
Moran
Partner
Litigation
Laura advises clients, primarily in the pharmaceutical and life sciences industries, on patent disputes. She has experience representing clients in complex litigation, including Hatch-Waxman litigation, inter partes review proceedings, and arbitration involving patent rights. She is experienced in practicing before the district courts, the Federal Circuit, and the Patent Trial and Appeal Board. Laura has also provided support to transactional matters, including by conducting intellectual property portfolio analysis.
Adept at persuasive brief writing, clients turn to Laura to craft compelling narratives. Well-versed in e-Discovery, she has extensive experience managing large scale document collections and reviews. Laura is effective at managing large case teams and routinely oversees large portfolios of matters for marquee firm clients.
Laura maintains an active pro bono practice and has represented victims of domestic violence in both family and matrimonial cases.
- Representing Novo Nordisk in pending Hatch-Waxman patent infringement lawsuits brought against six generic pharmaceutical manufacturers concerning Novo Nordisk’s blockbuster type 2 diabetes therapy and best-selling product Ozempic®.
- Representing Novo Nordisk in a series of Hatch-Waxman patent litigations dating back to 2017 relating to its blockbuster type 2 diabetes drug Victoza®, including ongoing cases against three ANDA filers. Prevailing in claim construction proceedings against prior opponents has helped lead to favorable confidential settlements in each past matter.
- Representing Novo Nordisk in pending patent infringement lawsuits brought against four ANDA filers concerning Novo Nordisk’s weight-loss treatment Saxenda®.
- Represented Pfizer and UCB in a series of District Court and PTAB trials concerning the drug Toviaz®. In the first trial against five defendants, the District Court ruled in Pfizer and UCB’s favor on all issues. In the second trial, the District Court ruled in Pfizer and UCB’s favor on all issues immediately upon the close of evidence. The PTAB upheld all challenged claims and the Federal Circuit affirmed.
- Represented Novo Nordisk as patent owner in an inter partes review filed by a competitor concerning methods of nanofiltering recombinant therapeutic proteins. The PTAB upheld all challenged claims in Novo Nordisk’s patent.
- Represented Swiss biopharmaceutical company IBSA in Hatch-Waxman litigations concerning its products Flector® and Tirosint®.
- Representing Novo Nordisk in pending Hatch-Waxman patent infringement lawsuits brought against six generic pharmaceutical manufacturers concerning Novo Nordisk’s blockbuster type 2 diabetes therapy and best-selling product Ozempic®.
- Representing Novo Nordisk in a series of Hatch-Waxman patent litigations dating back to 2017 relating to its blockbuster type 2 diabetes drug Victoza®, including ongoing cases against three ANDA filers. Prevailing in claim construction proceedings against prior opponents has helped lead to favorable confidential settlements in each past matter.
- Representing Novo Nordisk in pending patent infringement lawsuits brought against four ANDA filers concerning Novo Nordisk’s weight-loss treatment Saxenda®.
- Represented Pfizer and UCB in a series of District Court and PTAB trials concerning the drug Toviaz®. In the first trial against five defendants, the District Court ruled in Pfizer and UCB’s favor on all issues. In the second trial, the District Court ruled in Pfizer and UCB’s favor on all issues immediately upon the close of evidence. The PTAB upheld all challenged claims and the Federal Circuit affirmed.
- Represented Novo Nordisk as patent owner in an inter partes review filed by a competitor concerning methods of nanofiltering recombinant therapeutic proteins. The PTAB upheld all challenged claims in Novo Nordisk’s patent.
- Represented Swiss biopharmaceutical company IBSA in Hatch-Waxman litigations concerning its products Flector® and Tirosint®.
Recognition Recognition Recognition
Recognition Recognition Recognition
The Legal 500
2023
Recognized for Patent Litigation
Patexia
2023
Recognized among the Top ANDA Attorneys
The Legal 500
2023
Recognized for Patent Litigation
Patexia
2023
Recognized among the Top ANDA Attorneys